Cargando…

PI3k inhibitors (BKM120 and BYL719) as radiosensitizers for head and neck squamous cell carcinoma during radiotherapy

Approximately 500,000 new cases of head and neck squamous cell carcinoma (HNSCC) are reported annually. Radiation therapy is an important treatment for oral squamous cell carcinoma (OSCC). The survival rate of patients with HNSCC remained low (50%) in decades because of radiation therapy failure cau...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chuang, Fu-Cheng, Wang, Chih-Chun, Chen, Jian-Han, Hwang, Tzer-Zen, Yeh, Shyh-An, Su, Yu-Chieh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817006/ https://www.ncbi.nlm.nih.gov/pubmed/33471836 http://dx.doi.org/10.1371/journal.pone.0245715

Ejemplares similares

Discovering Synergistic Compounds with BYL-719 in PI3K Overactivated Basal-like PDXs
por: Boyd, David C., et al.
Publicado: (2023)

HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma
por: Meister, Kara S., et al.
Publicado: (2019)

Targeting Phosphatidylinositide3-Kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinoma
por: Liu, Wei-Lin, et al.
Publicado: (2014)

Efficacy of Providing the PI3K p110α Inhibitor BYL719 (Alpelisib) to Middle-Aged Mice in Their Diet
por: Hedges, Christopher P., et al.
Publicado: (2021)

Phase I study of alpelisib (BYL719), an α‐specific PI3K inhibitor, in Japanese patients with advanced solid tumors
por: Ando, Yuichi, et al.
Publicado: (2019)

Combined Treatment with PI3K Inhibitors BYL-719 and CAL-101 Is a Promising Antiproliferative Strategy in Human Rhabdomyosarcoma Cells
por: Piazzi, Manuela, et al.
Publicado: (2022)

BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells
por: Yu, Yaya, et al.
Publicado: (2023)

The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models
por: Nölting, Svenja, et al.
Publicado: (2017)

Targeting PI3K/AKT/mTOR Signaling Pathway as a Radiosensitization in Head and Neck Squamous Cell Carcinomas
por: Su, Yu-Chieh, et al.
Publicado: (2022)

PI3K Inhibition by BKM120 Results in Antiproliferative Effects on Corticotroph Tumor Cells
por: Oliveira, Helen A, et al.
Publicado: (2021)

Activity of BKM120 and BEZ235 against Lymphoma Cells
por: Civallero, Monica, et al.
Publicado: (2015)

Inhibitory effect of NVP-BKM120 on cholangiocarcinoma cell growth
por: Padthaisong, Sureerat, et al.
Publicado: (2018)

BKM120 induces apoptosis and inhibits tumor growth in medulloblastoma
por: Zhao, Ping, et al.
Publicado: (2017)

Combination therapy with BYL719 and LEE011 is synergistic and causes a greater suppression of p-S6 in triple negative breast cancer
por: Yuan, Yuan, et al.
Publicado: (2019)

Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy
por: Peng, Xin, et al.
Publicado: (2021)

Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant
por: Jacquemetton, Julien, et al.
Publicado: (2021)

Phase II study of BKM120 in patients with advanced esophageal squamous cell carcinoma (EPOC1303)
por: Kojima, Takashi, et al.
Publicado: (2022)

Correction to: Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy
por: Peng, Xin, et al.
Publicado: (2021)

5-Methoxytryptophan Sensitizing Head and Neck Squamous Carcinoma Cell to Cisplatitn Through Inhibiting Signal Transducer and Activator of Transcription 3 (STAT3)
por: Su, Yu-Chieh, et al.
Publicado: (2022)

Mouse–human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck
por: Kim, Hye Ryun, et al.
Publicado: (2020)

BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair
por: Zhang, Shaolu, et al.
Publicado: (2021)

Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas
por: Anderson, Jennifer L., et al.
Publicado: (2015)

Apoptin Overexpression Efficiently Amplified Cytotoxic Effects of PI3K Inhibition Using BKM120 in Lymphoblastic Leukemia Cell Lines
por: Anjam-Najmedini, Ali, et al.
Publicado: (2022)

Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer
por: Wang, Dong, et al.
Publicado: (2016)

Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells
por: Wang, Lei, et al.
Publicado: (2019)

BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma
por: Speranza, Maria-Carmela, et al.
Publicado: (2016)

Treatment Sequences in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Cetuximab Followed by Immunotherapy or Vice Versa
por: Yang, Chuan-Chien, et al.
Publicado: (2022)

Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells
por: Hu, Y, et al.
Publicado: (2015)

eIF4E and 4EBP1 are prognostic markers of head and neck squamous cell carcinoma recurrence after definitive surgery and adjuvant radiotherapy
por: Huang, Chung-I., et al.
Publicado: (2019)

Antitumor effects and mechanisms of olaparib in combination with carboplatin and BKM120 on human triple-negative breast cancer cells
por: Zhao, Hui, et al.
Publicado: (2018)

Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats
por: Netland, I. A., et al.
Publicado: (2016)

BKM120 sensitizes C6 glioma cells to temozolomide via suppression of the PI3K/Akt/NF-κB/MGMT signaling pathway
por: Li, Mao, et al.
Publicado: (2017)

Blockade efficacy of MEK/ERK-dependent autophagy enhances PI3K/Akt inhibitor NVP-BKM120's therapeutic effectiveness in lung cancer cells
por: Ren, Hui, et al.
Publicado: (2016)

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
por: Garrido-Castro, Ana C., et al.
Publicado: (2020)

Tegafur-Uracil versus 5-Fluorouracil in Combination with Cisplatin and Cetuximab in Elderly Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Propensity Score Matching Analysis
por: Hsieh, Meng-Che, et al.
Publicado: (2021)

NVP-BKM120 inhibits colon cancer growth via FoxO3a-dependent PUMA induction
por: Yang, Shida, et al.
Publicado: (2017)

Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors
por: Ando, Yuichi, et al.
Publicado: (2014)

Disulfiram and BKM120 in Combination with Chemotherapy Impede Tumor Progression and Delay Tumor Recurrence in Tumor Initiating Cell-Rich TNBC
por: Wu, Ling, et al.
Publicado: (2019)

NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations
por: PARK, EUNJU, et al.
Publicado: (2011)

BKM-react, an integrated biochemical reaction database
por: Lang, Maren, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ig1dgjkm5hjngseiaea9ds8njo